

CLAIMS:

1. An oligomeric compound, wherein the oligomeric compound is ISIS 681257, for use in treating or preventing a disease or condition in a human, wherein the treatment comprises administering not more than 500mg of the oligomeric compound to the human during a dosing period.
2. The oligomeric compound for use according to claim 1, wherein the treatment comprises administering not more than 250mg of the oligomeric compound to the human during the dosing period.
3. The oligomeric compound for use according to claim 1, wherein the treatment comprises administering not more than 100mg of the oligomeric compound to the human during the dosing period.
4. The oligomeric compound for use according to claim 1, wherein the treatment comprises administering not more than 50mg of the oligomeric compound to the human during the dosing period.
5. The oligomeric compound for use according to claim 1, wherein the treatment comprises administering not more than 25mg of the oligomeric compound to the human during the dosing period.
6. The oligomeric compound for use according to claim 1, wherein the treatment comprises administering not more than 15mg of the oligomeric compound to the human during the dosing period.
7. The oligomeric compound for use according to claim 1, wherein the treatment comprises administering not more than 60mg of the oligomeric compound to the human during the dosing period.
8. The oligomeric compound for use according to claim 1, wherein the treatment comprises administering not more than 40mg of the oligomeric compound to the human during the dosing period.
9. The oligomeric compound for use according to claim 1, wherein the treatment comprises administering not more than 30mg of the oligomeric compound to the human during the dosing period.
10. The oligomeric compound for use according to claim 1, wherein the treatment comprises administering not more than 20mg of the oligomeric compound to the human during the dosing period.
11. The oligomeric compound for use according to claim 1, wherein the treatment comprises administering not more than 10mg of the oligomeric compound to the human during the dosing period.

12. The oligomeric compound for use according to claim 1, wherein the treatment comprises administering not more than 5mg of the oligomeric compound to the human during the dosing period.
13. The oligomeric compound for use according to any of claims 1-12, wherein the dosing period is three months.
14. The oligomeric compound for use according to any of claims 1-12, wherein the dosing period is two months.
15. The oligomeric compound for use according to any of claims 1-12, wherein the dosing period is one month.
16. The oligomeric compound for use according to any of claims 1-12, wherein the dosing period is four weeks.
17. The oligomeric compound for use according to any of claims 1-12, wherein the dosing period is three weeks.
18. The oligomeric compound for use according to any of claims 1-12, wherein the dosing period is two weeks.
19. The oligomeric compound for use according to any of claims 1-12, wherein the dosing period is one week.
20. The oligomeric compound for use according to any preceding claim, wherein the treatment comprises administering a unit dose comprising not more than 125mg of the oligomeric compound.
21. The oligomeric compound for use according to any preceding claim, wherein the treatment comprises administering a unit dose comprising not more than 100mg of the oligomeric compound.
22. The oligomeric compound for use according to any preceding claim, wherein the treatment comprises administering a unit dose comprising not more than 75mg of the oligomeric compound.

23. The oligomeric compound for use according to any preceding claim, wherein the treatment comprises administering a unit dose comprising not more than 50mg of the oligomeric compound.
24. The oligomeric compound for use according to any preceding claim, wherein the treatment comprises administering a unit dose comprising not more than 25mg of the oligomeric compound.
25. The oligomeric compound for use according to any preceding claim, wherein the treatment comprises administering a unit dose comprising not more than 15mg of the oligomeric compound.
26. The oligomeric compound for use according to any preceding claim, wherein the treatment comprises administering a unit dose comprising not more than 60mg of the oligomeric compound.
27. The oligomeric compound for use according to any preceding claim, wherein the treatment comprises administering a unit dose comprising not more than 40mg of the oligomeric compound.
28. The oligomeric compound for use according to any preceding claim, wherein the treatment comprises administering a unit dose comprising not more than 30mg of the oligomeric compound.
29. The oligomeric compound for use according to any preceding claim, wherein the treatment comprises administering a unit dose comprising not more than 20mg of the oligomeric compound.
30. The oligomeric compound for use according to any preceding claim, wherein the treatment comprises administering a unit dose comprising not more than 10mg of the oligomeric compound.
31. The oligomeric compound for use according to any preceding claim, wherein the treatment comprises administering a unit dose comprising not more than 5mg of the oligomeric compound.
32. The oligomeric compound for use according to any of claims 14-19, wherein the treatment comprises administering a unit dose comprising not less than 1mg of the oligomeric compound.
33. The oligomeric compound for use according to claim 32, wherein the treatment comprises administering a unit dose comprising not less than 2.5mg of the oligomeric compound
34. The oligomeric compound for use according to claim 32, wherein the treatment comprises administering a unit dose comprising not less than 5mg of the oligomeric compound

35. The oligomeric compound for use according to any of claims 20-34, wherein the treatment comprises administering a unit dose of from 75mg to 85 mg, and optionally a unit dose of 80mg.
36. The oligomeric compound for use according to any of claims 20-34, wherein the treatment comprises administering a unit dose of from 55mg to 65 mg, and optionally a unit dose of 60mg.
37. The oligomeric compound for use according to any of claims 20-34, wherein the treatment comprises administering a unit dose of from 35mg to 45mg, and optionally a unit dose of 40mg.
38. The oligomeric compound for use according to any of claims 20-34, wherein the treatment comprises administering a unit dose of from 25mg to 35mg, and optionally a unit dose of 30mg.
39. The oligomeric compound for use according to any of claims 20-34, wherein the treatment comprises administering a unit dose of from 15mg to 25 mg, and optionally a unit dose of 20mg.
40. The oligomeric compound for use according to any of claims 20-34, wherein the treatment comprises administering a unit dose of from 5mg to 15mg, and optionally a unit dose of 10mg.
41. The oligomeric compound for use according to any of claims 20-34, wherein the treatment comprises administering a unit dose of from 1mg to 10mg, and optionally a unit dose of 5mg.
42. The oligomeric compound for use according to any of claims 20-41, wherein the treatment comprises administering not more than 1 unit dose to the human during the dosing period.
43. The oligomeric compound for use according to any of claims 20-41, wherein the treatment comprises administering not more than 2 unit doses to the human during the dosing period.
44. The oligomeric compound for use according to any of claims 20-41, wherein the treatment comprises administering not more than 3 unit doses to the human during the dosing period.
45. The oligomeric compound for use according to any of claims 20-41, wherein the treatment comprises administering not more than 4 unit doses to the human during the dosing period.
46. The oligomeric compound for use according to any of claims 20-41, wherein the treatment comprises administering not more than 5 unit doses to the human during the dosing period.

47. The oligomeric compound for use according to any of claims 20-41, wherein the treatment comprises administering not more than 6 unit doses to the human during the dosing period.
48. The oligomeric compound for use according to any of claims 1-47, wherein: (i) the treatment comprises administering not more than 100mg of the oligomeric compound to the human during the dosing period; and (ii) the dosing period is three months.
49. The oligomeric compound for use according to claim 48, wherein (i) the treatment comprises administering not more than 100mg of the oligomeric compound to the human during the dosing period; (ii) the dosing period is three months; and (iii) the treatment comprises administering not more than one unit dose to the human during the dosing period.
50. The oligomeric compound according to claim 48 or claim 49, wherein the treatment comprises administering from 75mg to 85 mg, optionally 80mg, of the oligomeric compound to the human during the dosing period.
51. The oligomeric compound for use according to any of claims 1-47, wherein: (i) the treatment comprises administering not more than 100mg of the oligomeric compound to the human during the dosing period; and (ii) the dosing period is two months.
52. The oligomeric compound for use according to claim 51, wherein (i) the treatment comprises administering not more than 100mg of the oligomeric compound to the human during the dosing period; (ii) the dosing period is two months; and (iii) the treatment comprises administering not more than one unit dose to the human during the dosing period.
53. The oligomeric compound according to claim 51 or claim 52, wherein the treatment comprises administering from 75mg to 85 mg, optionally 80mg, of the oligomeric compound to the human during the dosing period.
54. The oligomeric compound for use according to any of claims 1-47, wherein: (i) the treatment comprises administering not more than 100mg of the oligomeric compound to the human during the dosing period; and (ii) the dosing period is one month.
55. The oligomeric compound for use according to claim 54, wherein (i) the treatment comprises administering not more than 100mg of the oligomeric compound to the human during the dosing period; (ii) the dosing period is one month; and (iii) the treatment comprises administering not more than one unit dose to the human during the dosing period.

56. The oligomeric compound according to claim 54 or claim 55, wherein the treatment comprises administering from 75mg to 85 mg, optionally 80mg, of the oligomeric compound to the human during the dosing period.
57. The oligomeric compound for use according to any of claims 1-47, wherein: (i) the treatment comprises administering not more than 75mg of the oligomeric compound to the human during the dosing period; and (ii) the dosing period is one month.
58. The oligomeric compound for use according to claim 57, wherein (i) the treatment comprises administering not more than 75mg of the oligomeric compound to the human during the dosing period; (ii) the dosing period is one month; and (iii) the treatment comprises administering not more than one unit dose to the human during the dosing period.
59. The oligomeric compound according to claim 57 or claim 58, wherein the treatment comprises administering from 55mg to 65mg, optionally 60mg, of the oligomeric compound to the human during the dosing period.
60. The oligomeric compound for use according to any of claims 1-47, wherein: (i) the treatment comprises administering not more than 60mg of the oligomeric compound to the human during the dosing period; and (ii) the dosing period is one month.
61. The oligomeric compound for use according to claim 60, wherein (i) the treatment comprises administering not more than 60mg of the oligomeric compound to the human during the dosing period; (ii) the dosing period is one month; and (iii) the treatment comprises administering not more than one unit dose to the human during the dosing period.
62. The oligomeric compound according to claim 60 or claim 61, wherein the treatment comprises administering from 55mg to 65mg, optionally 60 mg, of the oligomeric compound to the human during the dosing period.
63. The oligomeric compound according to claim 61 or claim 62, wherein the treatment comprises administering 60 mg, of the oligomeric compound to the human during the dosing period.
64. The oligomeric compound according to claim 61 or claim 62, wherein the treatment comprises administering 40 mg, of the oligomeric compound to the human during the dosing period.

65. The oligomeric compound according to claim 61 or claim 62, wherein the treatment comprises administering 20 mg, of the oligomeric compound to the human during the dosing period.
66. The oligomeric compound for use according to any of claims 1-47, wherein: (i) the treatment comprises administering not more than 50mg of the oligomeric compound to the human during the dosing period; and (ii) the dosing period is one week.
67. The oligomeric compound for use according to claim 66, wherein (i) the treatment comprises administering not more than 50mg of the oligomeric compound to the human during the dosing period; (ii) the dosing period is one week; and (iii) the treatment comprises administering not more than one unit dose to the human during the dosing period.
68. The oligomeric compound according to claim 66 or claim 67, wherein the treatment comprises administering from 35mg to 45mg, optionally 40mg, of the oligomeric compound to the human during the dosing period.
69. The oligomeric compound according to claim 66 or claim 67, wherein the treatment comprises administering from 25mg to 35mg, optionally 30mg, of the oligomeric compound to the human during the dosing period.
70. The oligomeric compound according to claim 66 or claim 67, wherein the treatment comprises administering from 15mg to 25 mg, optionally 20mg, of the oligomeric compound to the human during the dosing period.
71. The oligomeric compound according to claim 66 or claim 67, wherein the treatment comprises administering from 5mg to 15mg, optionally 10mg, of the oligomeric compound to the human during the dosing period.
72. The oligomeric compound according to claim 66 or claim 67, wherein the treatment comprises administering from 1mg to 10mg, optionally 5mg, of the oligomeric compound to the human during the dosing period.
73. The oligomeric compound for use according to any of claims 1-47, wherein: (i) the treatment comprises administering not more than 80 mg of the oligomeric compound to the human during the dosing period; and (ii) the dosing period is four weeks.

74. The oligomeric compound for use according to claim 73, wherein (i) the treatment comprises administering not more than 80mg of the oligomeric compound to the human during the dosing period; (ii) the dosing period is four weeks; and (iii) the treatment comprises administering not more than one unit dose to the human during the dosing period.
75. The oligomeric compound for use according to claim 73, wherein (i) the treatment comprises administering not more than 60mg of the oligomeric compound to the human during the dosing period; (ii) the dosing period is four weeks; and (iii) the treatment comprises administering not more than one unit dose to the human during the dosing period.
76. The compound according to claim 73 to 75, wherein the treatment comprises administering 35mg to 45mg, optionally 40mg, of the oligomeric compound to the human during the dosing period.
77. The compound according to claim 73 to 75, wherein the treatment comprises administering 25mg to 35mg, optionally 30mg, of the oligomeric compound to the human during the dosing period.
78. The compound according to claim 73 to 75, wherein the treatment comprises administering 15mg to 25 mg, optionally 20mg, of the oligomeric compound to the human during the dosing period.
79. The oligomeric compound for use according to any of claims 1-47, wherein: (i) the treatment comprises administering not more than 250mg of the oligomeric compound to the human during the dosing period; and (ii) the dosing period is four weeks.
80. The oligomeric compound for use according to claim 79, wherein the treatment comprises administering 40 mg of the oligomeric compound six times during the dosing period.
81. The oligomeric compound for use according to claim 79, wherein the treatment comprises administering 40 mg of the oligomeric compound four times during the dosing period.
82. The oligomeric compound for use according to claim 79 or claim 80, wherein (i) the treatment comprises administering 40 mg of the oligomeric compound six times during the dosing period, and (ii) once per week thereafter.
83. The oligomeric compound for use according to claim 79 or claim 80, wherein (i) the treatment comprises administering 40 mg of the oligomeric compound four times during the dosing period, and (ii) once per week thereafter.

84. The oligomeric compound for use according to claim 79, wherein the treatment comprises administering 30 mg of the oligomeric compound six times during the dosing period.
85. The oligomeric compound for use according to claim 79, wherein the treatment comprises administering 30 mg of the oligomeric compound four times during the dosing period.
86. The oligomeric compound for use according to claim 79, wherein (i) the treatment comprises administering 30 mg of the oligomeric compound six times during the dosing period, and (ii) once per week thereafter.
87. The oligomeric compound for use according to claim 79, wherein (i) the treatment comprises administering 30 mg of the oligomeric compound four times during the dosing period, and (ii) once per week thereafter.
88. The oligomeric compound for use according to claim 79, wherein the treatment comprises administering 20 mg of the oligomeric compound six times during the dosing period.
89. The oligomeric compound for use according to claim 79, wherein the treatment comprises administering 20 mg of the oligomeric compound four times during the dosing period.
90. The oligomeric compound for use according to claim 79, wherein (i) the treatment comprises administering 20 mg of the oligomeric compound six times during the dosing period, and (ii) once per week thereafter.
91. The oligomeric compound for use according to claim 79 or claim 89, wherein (i) the treatment comprises administering 20 mg of the oligomeric compound four times during the dosing period, and (ii) once per week thereafter.
92. The oligomeric compound for use according to claim 79, wherein the treatment comprises administering 10 mg of the oligomeric compound four times during the dosing period.
93. The oligomeric compound for use according to claim 79 or claim 92, wherein (i) the treatment comprises administering 10 mg of the oligomeric compound four times during the dosing period, and (ii) once per week thereafter.
94. The oligomeric compound for use according to claim 79, wherein the treatment comprises administering 5 mg of the oligomeric compound four times during the dosing period.

95. The oligomeric compound for use according to claim 79 or claim 94, wherein (i) the treatment comprises administering 5 mg of the oligomeric compound four times during the dosing period, and (ii) once per week thereafter.
96. The oligomeric compound for use according to any of claims 1-95, wherein the human is at enhanced risk for cardiovascular events due to chronically elevated plasma Lp(a) levels.
97. The oligomeric compound for use according to any of claims 1-95, wherein the disease or condition is selected from calcific aortic valve stenosis with elevated Lp(a), elevated cardiovascular risk with elevated Lp(a), recurrent cardiovascular events with elevated Lp(a), or one or more symptoms of a cardiovascular disease or disorder associated with elevated Lp(a).
98. The oligomeric compound for use according to any preceding claim, wherein the oligomeric compound is administered to the human by injection.
99. The oligomeric compound for use according to claim 98, wherein the oligomeric compound is administered to the human by subcutaneous injection.
100. The oligomeric compound for use according to claim 98 or claim 99, wherein the oligomeric compound is formulated in a sterile liquid and optionally wherein each unit dose of the oligomeric compound is not more than 1 mL of the sterile liquid.
101. The oligomeric compound for use according to claim 100, wherein each unit dose of the oligomeric compound is not more than 0.8 mL of the sterile liquid.
102. The oligomeric compound for use according to claim 100, wherein each unit dose of the oligomeric compound is not more than 0.5 mL of the sterile liquid.
103. The oligomeric compound for use according to claim 100, wherein each unit dose of the oligomeric compound is not more than 0.4 mL of the sterile liquid.
104. The oligomeric compound for use according to claim 100, wherein each unit dose of the oligomeric compound is not more than 0.25 mL of the sterile liquid.

105. The oligomeric compound for use according to claim 100, wherein each unit dose of the oligomeric compound is not more than 0.2 mL of the sterile liquid.
106. The oligomeric compound for use according to any of claims 100 to 105, wherein the sterile liquid is water.
107. The oligomeric compound for use according to any of claims 100 to 105, wherein the sterile liquid is water with a sodium phosphate buffer.
108. The oligomeric compound for use according to any of claims 100 to 105, wherein the sterile liquid is water with a sodium phosphate buffer and sodium chloride.
109. The oligomeric compound for use according to any preceding claim, wherein the treatment reduces the fasting plasma Lp(a) concentration in the human by at least 50%, when the fasting plasma Lp(a) concentration in the human is measured at the start and end of the dosing period.
110. The oligomeric compound for use according to any preceding claim, wherein the treatment reduces the fasting plasma Lp(a) concentration in the human by at least 75%, when the fasting plasma Lp(a) concentration in the human is measured at the start and end of the dosing period
111. The oligomeric compound for use according to any preceding claim, wherein the treatment reduces the fasting plasma Lp(a) concentration in the human by at least 80%, when the fasting plasma Lp(a) concentration in the human is measured at the start and end of the dosing period.
112. The oligomeric compound for use according to any preceding claim, wherein the treatment reduces the fasting plasma Lp(a) concentration in the human by at least 85%, when the fasting plasma Lp(a) concentration in the human is measured at the start and end of the dosing period.
113. A pharmaceutical composition comprising an oligomeric compound and one or more pharmaceutically acceptable carriers or diluents, wherein the oligomeric compound is ISIS 681257, and wherein the pharmaceutical composition contains not more than 125mg of the oligomeric compound.
114. The pharmaceutical composition of claim 113, wherein the pharmaceutical composition contains not more than 100mg of the oligomeric compound.
115. The pharmaceutical composition of claim 113, wherein the pharmaceutical composition contains not more than 75mg of the oligomeric compound.

116. The pharmaceutical composition of claim 113, wherein the pharmaceutical composition contains not more than 60mg of the oligomeric compound.
117. The pharmaceutical composition of claim 113, wherein the pharmaceutical composition contains not more than 50mg of the oligomeric compound.
118. The pharmaceutical composition of claim 113, wherein the pharmaceutical composition contains not more than 40mg of the oligomeric compound.
119. The pharmaceutical composition of claim 113, wherein the pharmaceutical composition contains not more than 30mg of the oligomeric compound.
120. The pharmaceutical composition of claim 113, wherein the pharmaceutical composition contains not more than 25mg of the oligomeric compound.
121. The pharmaceutical composition of claim 113, wherein the pharmaceutical composition contains not more than 20mg of the oligomeric compound.
122. The pharmaceutical composition of claim 113, wherein the pharmaceutical composition contains not more than 15mg of the oligomeric compound.
123. The pharmaceutical composition of claim 113, wherein the pharmaceutical composition contains not more than 10mg of the oligomeric compound.
124. The pharmaceutical composition of claim 113, wherein the pharmaceutical composition contains not more than 5mg of the oligomeric compound.
125. The pharmaceutical composition of claim 113, wherein the pharmaceutical composition contains not less than 1mg of the oligomeric compound.
126. The pharmaceutical composition of claim 113, wherein the pharmaceutical composition contains not less than 2.5mg of the oligomeric compound.
127. The pharmaceutical composition of claim 113, wherein the pharmaceutical composition contains not less than 5mg of the oligomeric compound.

128. The pharmaceutical composition of claim 113, wherein the pharmaceutical composition contains not less than 10mg of the oligomeric compound.
129. The pharmaceutical composition according to claim 113, wherein the composition comprises from 75mg to 85 mg, and optionally 80mg, of the oligomeric compound.
130. The pharmaceutical composition according to claim 113, wherein the composition comprises from 55mg to 65 mg, and optionally 60mg, of the oligomeric compound.
131. The pharmaceutical composition according to claim 113, wherein the composition comprises from 35mg to 45mg, and optionally 40mg, of the oligomeric compound.
132. The pharmaceutical composition according to claim 113, wherein the composition comprises from 25mg to 35mg, and optionally 30mg, of the oligomeric compound.
133. The pharmaceutical composition according to claim 113, wherein the composition comprises from 15mg to 25 mg, and optionally 20mg, of the oligomeric compound.
134. The pharmaceutical composition according to claim 113, wherein the composition comprises from 5mg to 15mg, and optionally 10mg, of the oligomeric compound.
135. The pharmaceutical composition according to any of claims 113-134, wherein the composition is formulated for administration to a human by injection.
136. The pharmaceutical composition according to claim 135, wherein the oligomeric compound is formulated in a sterile liquid and optionally the composition is not more than 1 mL of the sterile liquid.
137. The pharmaceutical composition according to claim 135, wherein the pharmaceutical composition is not more than 0.8 mL of the sterile liquid.
138. The pharmaceutical composition according to claim 135, wherein the pharmaceutical composition is not more than 0.5 mL of the sterile liquid.
139. The pharmaceutical composition according to claim 135, wherein the pharmaceutical composition is not more than 0.4 mL of the sterile liquid.

140. The pharmaceutical composition according to claim 135, wherein the pharmaceutical composition is not more than 0.25 mL of the sterile liquid.
141. The pharmaceutical composition according to claim 135, wherein the pharmaceutical composition is not more than 0.2 mL of the sterile liquid.
142. The pharmaceutical composition according to any of claims 135 to 141, wherein the sterile liquid is water.
143. The pharmaceutical composition according to any of claims 135 to 141, wherein the sterile liquid is water with a sodium phosphate buffer.
144. The pharmaceutical composition according to any of claims 135 to 141, wherein the sterile liquid is water with a sodium phosphate buffer and sodium chloride.
145. The pharmaceutical composition according to any of claims 113-144, wherein administering the composition to a human reduces the fasting plasma Lp(a) concentration in the human by at least 50%, when the fasting plasma Lp(a) concentration in the human is measured at the start and end of the dosing period.
146. The pharmaceutical composition according to any of claims 113-144, wherein administering the composition to a human reduces the fasting plasma Lp(a) concentration in the human by at least 75%, when the fasting plasma Lp(a) concentration in the human is measured at the start and end of the dosing period.
147. The pharmaceutical composition according to any of claims 113-144, wherein administering the composition to a human reduces the fasting plasma Lp(a) concentration in the human by at least 80%, when the fasting plasma Lp(a) concentration in the human is measured at the start and end of the dosing period.
148. The pharmaceutical composition according to any of claims 113-144, wherein administering the composition to a human reduces the fasting plasma Lp(a) concentration in the human by at least 85%, when the fasting plasma Lp(a) concentration in the human is measured at the start and end of the dosing period.

149. A method for producing the pharmaceutical composition according to any of claims 113-148, wherein the method comprises combining not more than 125mg of the oligomeric compound with one or more pharmaceutically acceptable diluents, excipients or carriers.
150. A packaged pharmaceutical product comprising: (a) multiple unit dosage forms each comprising a pharmaceutical composition according to any of claims 113-148; and (b) printed instructions describing the administration of the unit dosage forms for a treatment as set forth in any of claims 1-112.
151. A sterile sealed container which contains a pharmaceutical composition according to any one of claims 113-148.
152. The sterile container according to claim 151, wherein the container is a vial.
153. The sterile container according to claim 151, wherein the container is a syringe.
154. A packaged pharmaceutical product comprising: (a) multiple unit dosage forms each comprising a sealed sterile container according to any of claims 151-153; and (b) printed instructions describing the administration of the unit dosage forms for a treatment as set forth in any of claims 1-112.
155. The method of claim 114, wherein the method comprises a treatment as set forth in any of claims 1-112.
156. Use of ISIS 681257 in the manufacture of a pharmaceutical composition according to any of claims 113-148, a packaged pharmaceutical composition according to claim 150 or 154, or a sterile sealed container according to any of claims 151-153.